Randomized Clinical Study of Nitazoxanide Compared to Metronidazole in the Treatment of Symptomatic Giardiasis in Children from Northern Peru
Overview
Pharmacology
Authors
Affiliations
Background: Enteric infection by Giardia intestinalis is a common cause of diarrhoea world-wide and a significant cause of morbidity in children.
Aim: To compare the efficacy and safety of nitazoxanide and metronidazole in the treatment of diarrhoea caused by G. intestinalis in children.
Methods: A total of 110 children presenting with diarrhoea caused by G. intestinalis were randomized to treatment with either a 3-day course of nitazoxanide (100 mg b.d., age range 2-3 years; 200 mg b.d., age range 4-11 years) or a 5-day course of metronidazole (125 mg b.d., age range 2-5 years; 250 mg b.d., age range 6-11 years). The patients were followed-up for a determination of clinical response 7 days after the initiation of treatment, and two subsequent stool samples were collected for parasitological examination.
Results: Diarrhoea had resolved in 47 children out of 55 (85%) in the nitazoxanide treatment group before the day 7 follow-up visit, compared to 44 out of 55 (80%) for metronidazole. Diarrhoea resolved within 4 days in most cases. Only mild, transient adverse events were reported.
Conclusions: A 3-day course of nitazoxanide suspension is as efficacious as a standard 5-day course of metronidazole suspension in treating giardiasis in children.
Guga G, Houpt E, Elwood S, Liu J, Kimathi C, Mosha R PLoS One. 2023; 18(12):e0294110.
PMID: 38127924 PMC: 10734999. DOI: 10.1371/journal.pone.0294110.
Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.
Calvo-Alvarez E, Dolci M, Perego F, Signorini L, Parapini S, DAlessandro S Microorganisms. 2022; 10(7).
PMID: 35889004 PMC: 9320270. DOI: 10.3390/microorganisms10071284.
DeBoer M, Platts-Mills J, Elwood S, Scharf R, McDermid J, Wanjuhi A PLoS Med. 2021; 18(9):e1003617.
PMID: 34582462 PMC: 8478246. DOI: 10.1371/journal.pmed.1003617.
Synthesis, in vitro bioassays, and computational study of heteroaryl nitazoxanide analogs.
Ahmed T, Rahman S, Asaduzzaman M, Islam A, Chowdhury A Pharmacol Res Perspect. 2021; 9(3):e00800.
PMID: 34086411 PMC: 8177060. DOI: 10.1002/prp2.800.
Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.
Li X, Peng T Front Pharmacol. 2021; 12:660710.
PMID: 34017257 PMC: 8129523. DOI: 10.3389/fphar.2021.660710.